Épidémiologie et traitement des infections par le VHC en Égypte


• On-going projects

- 2010: EC: FP7-HEALTH-2010-single-stage: Spontaneous clearance in Patients acutely infected with HCV: Immune profiling, Novel biomarkers and X-omics approaches (SPHINX) (scientific coordination: Matthew Albert).

- 2010: ANRS 12246 : Feasibility study for an ethnographic investigation of medical injections, a risk factor in Hepatitis C transmission, Greater Cairo, Egypt (scientific coordination: Naglaa El Nahal and Tamara Giles-Vernick).

- 2010: ANRS 12226 : Efficacy and safety of the combination nitazoxanide (NTZ) or vitamin D (Vit D), with pegylated interferon alpha-2b (PEG-IFN)/ribavirin (RBV) in Egyptian patients with untreated genotype 4 chronic hepatitis C: A phase III randomized open-label clinical trial (scientific coordination: Gamal Esmat and Arnaud Fontanet)

- 2009: ANRS 12216 (“contrat d’initiation”): Preclinical study for the evaluation of chemokine antagonism in chronic hepatitis C genotype 4 infection (scientific coordination: Mona Rafik and Matthew Albert) (15 000 euros).

- 2009: ANRS 12215: Cost-effectiveness of different antiviral treatment strategies in HCV-infected patients in Egypt: defining best starting and stopping criteria (scientific coordination: Mostafa K Mohamed and Yazdan Yazdanpanah) (150 000 euros).

- 2009: ANRS 12210: Symptomatic acute hepatitis C in Egypt (scientific coordination: Mostafa K Mohamed and Arnaud Fontanet). (765 000 euros).

- 2009: ANRS 12199: The inflammatory signature of viral hepatitis (scientific coordination: Mona Rafik and Matthew Albert). (308 000 euros).

- 2008: ANRS 12188: An investigation of serum factors that modulate HCV infectivity in an Egyptian cohort of acutely infected patients: role of quasispecies evolution, neutralising antibodies, serum amyloid A and lipoproteins (scientific coordination: Mohamed Abdel-Hamid and François-Loïc Cosset).

- 2008: ANRS 12184: Liver fibrosis evaluation among HCV genotype 4-infected patients in Egypt. Comparison of elastometry, histology and serum markers. (scientific coordination: Gamal Esmat and Philippe Bonnard). (200 000 euros).

- 2007: ANRS 12171: HCV transmission and transient HCV infection among healthcare workers in Cairo, Egypt C (scientific coordination: Mostafa Mohamed and Sylvia Taylor). (320 000 euros).

• Previous projects

- 2006: ANRS 12135: Immunology of acute hepatitis C (scientific coordination: Mona Rafik and Matthew Albert). (250 000 euros).

- 2005 : ANRS 12122: Acute hepatitis C: risk factors, spontaneous clearance, and response to treatment. (scientific coordination: Mostafa Mohamed and Arnaud Fontanet). (331 000 euros).

- 2005 : Wellcome Trust : Hepatitis C infection and clearance: associations with atherosclerosis and the metabolic syndrome. (scientific coordination: Mostafa Mohamed and  Nish Chaturvedi). (£284 000).

- 2005 : ANRS 12107 : Modes of intrafamilial transmission of HCV in endemic areas and study of human genetic factors associated with HCV infection. (scientific coordination: Mostafa Mohamed and Laurent Abel). (293 000 euros).

- 2005: PAI (French MFA and Egyptian Ministry of Higher Education) Imhotep: mobility grant (2005-6). (30 000 euros).

- 2002: ANRS 1279: cost-effectiveness of treatment strategies for hepatitis C in Egypt. (scientific coordination: Mostafa Mohamed and Michaël Schwarzinger). (109000 euros).

- 2001: ANRS 1213: efficacy and safety of treatment of acute hepatitis C with pegylated interferon alone. (scientific coordination: Mostafa Mohamed and Arnaud Fontanet). (431 000 euros). Drugs provided free of charge by Roche laboratories.

- 2001: ANRS 1211: efficacy and safety of treatment of chronic hepatitis C (genotype 4) with pegylated interferon and ribavirin. (scientific coordination: Mostafa Mohamed and Arnaud Fontanet). (520 000 euros). Drugs provided free of charge by Roche. laboratories.

- 2001: EC contract (ICA3-CT2000-30011): village cohort study of HCV incidence and progression in the Nile Delta (included in a larger project involving five Mediterranean countries; scientific coordination: Bernard Larouzé, INSERM U707). (500 000 euros).